Rabbit Polyclonal CGR19 Antibody

The CGR19 antibody is a monoclonal antibody developed to target specific epitopes associated with cancer-related antigens, particularly in the context of solid tumors. Initially identified during efforts to discover novel immunotherapies, CGR19 was engineered to bind selectively to cell surface proteins overexpressed in malignancies such as colorectal, pancreatic, or breast cancers. Its design leverages IgG-based frameworks for enhanced stability and effector functions, including antibody-dependent cellular cytotoxicity (ADCC) and phagocytosis (ADCP). Preclinical studies highlight its ability to inhibit tumor growth in xenograft models by disrupting pro-survival signaling pathways or blocking ligand-receptor interactions critical for cancer progression. CGR19 has also shown potential in combination therapies, synergizing with checkpoint inhibitors or chemotherapy to enhance antitumor efficacy. While its exact molecular target remains proprietary in many reports, ongoing research focuses on optimizing its specificity and reducing off-target effects. Current investigations explore its diagnostic utility in biomarker detection and therapeutic applications in minimal residual disease settings. As of recent updates, CGR19 is in early-phase clinical trials to evaluate safety and pharmacokinetics, positioning it as a promising candidate in next-generation oncology therapeutics.